Bachelor's degree: Southern medical University, Guangzhou, China.
Ph.D. degree: Southern medical University, Guangzhou, China.
Contact Infomation
Email: wenyang1@hku.hk
Research description
Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 can activate T cells by blocking the immunosuppressive signals of the tumor immune microenvironment, thereby restoring the immune system's anti-tumor killing effect. However, the resistance and low response rate of α-PD-1/PD-L1 therapy remains to be resolved. My current research focuses on the combination of PD-1 inhibitors and various other treatment strategies such as other immunosuppressants, chemotherapeutic drugs, metabolic drugs, and how to reverse the immune exhaustion state in tumors.
Publication
First/Co-First author publication
Wen Y, Sun X, Zeng L, Liang S, Li D, Chen X, Zeng F, Zhang C, Wang Q, Zhong Q, Deng L, Guo L. CDK4/6 Inhibitors Impede Chemoresistance and Inhibit Tumor Growth of Small Cell Lung Cancer. Adv Sci (Weinh). 2024 Oct;11(38):e2400666. doi: 10.1002/advs.202400666. Epub 2024 Aug 13. PMID: 39136283; PMCID: PMC11481398.
Wen Y, Lin A, Zhu W, Wei T, Luo P, Guo L, Zhang J. Catenin Alpha-2 Mutation Changes the Immune Microenvironment in Lung Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitors. Front Pharmacol. 2021 Jun 7;12:645862. doi: 10.3389/fphar.2021.645862. PMID: 34163353; PMCID: PMC8215613.
Wen Y, Deng L, Guo L. Difference of background in research and clinical practice between USA and China. J Thorac Dis. 2020 Jul;12(7):3809-3812. doi: 10.21037/jtd.2020.04.07. PMID: 32802461; PMCID: PMC7399414.
Liang S, Wang Q, Wen Y, Wang Y, Li M, Wang Q, Peng J, Guo L. Ligand-independent EphA2 contributes to chemoresistance in small-cell lung cancer by enhancing PRMT1-mediated SOX2 methylation. Cancer Sci. 2023 Mar;114(3):921-936. doi: 10.1111/cas.15653. Epub 2022 Dec 8. PMID: 36377249; PMCID: PMC9986087. (Co-first author)
Zhou J, Wen Y, Chen X, Guo L. Bioinformatic Analysis of Prognostic Value of SNTG2 with Immune Implications in Lung Adenocarcinoma. Int J Gen Med. 2022 May 24;15:5181-5196. doi: 10.2147/IJGM.S355393. PMID: 35637702; PMCID: PMC9148212. (Co-first author)
Co-author Publication
Tan Z, Chiu MS, Yue M, Kwok HY, Tse MH, Wen Y, Chen B, Yang D, Zhou D, Song YQ, Man K, Chen Z. Enhancing the efficacy of vaccinia-based oncolytic virotherapy by inhibiting CXCR2-mediated MDSC trafficking. J Leukoc Biol. 2024 Mar 29;115(4):633-646. doi: 10.1093/jleuko/qiad150. PMID: 38066571.
Zhou N, Luo P, Wen Y, Meng H, Zhang J. Immune Cell Infiltration Is a Strong Prognostic Indicator in Surgical Resection of SCLC. J Thorac Oncol. 2019 Oct;14(10):e242-e243. doi: 10.1016/j.jtho.2019.06.029. PMID: 31558242.
Zhang J, Zhou N, Deng H, Chen X, Chen Q, Wang Q, Sun L, Wen Y, Cao X, Luo Z, Zhang J, Zhu W, Guo L. Prognostic value of circulating tumor DNA using target next-generation sequencing in extensive-stage small-cell lung cancer. Lung Cancer. 2023 Apr;178:11-19. doi: 10.1016/j.lungcan.2023.01.015. Epub 2023 Feb 2. PMID: 36758321.
Zeng FR, Zhou XY, Zeng LG, Sun JC, He F, Mo W, Wen Y, Wang SY, Liu Q, Guo LL. Identification of key genes and pathway related to chemoresistance of small cell lung cancer through an integrative bioinformatics analysis. Ann Transl Med. 2022 Sep;10(18):968. doi: 10.21037/atm-22-3642. PMID: 36267705; PMCID: PMC9577795.
Li D, Tong Q, Lian Y, Chen Z, Zhu Y, Huang W, Wen Y, Wang Q, Liang S, Li M, Zheng J, Liu Z, Liu H, Guo L. Inhibition of lncRNA KCNQ1OT1 Improves Apoptosis and Chemotherapy Drug Response in Small Cell Lung Cancer by TGF-β1 Mediated Epithelial-to-Mesenchymal Transition. Cancer Res Treat. 2021 Oct;53(4):1042-1056. doi: 10.4143/crt.2020.1208. Epub 2021 Mar 9. PMID: 33705625; PMCID: PMC8524015.